Role of noncoding RNA in drug resistance of prostate cancer

• Main Authors: Lifeng Ding, Ruyue Wang, Danyang Shen, Sheng Cheng, Huan Wang, Zeyi Lu, Qiming Zheng, Liya Wang, Liqun Xia, Gonghui Li
• Format: Article
• Language: English
• Published: Nature Publishing Group 2021-06-01
• Series: Cell Death and Disease
• Online Access: https://doi.org/10.1038/s41419-021-03854-x

Abstract Prostate cancer is one of the most prevalent forms of cancer around the world. Androgen-deprivation treatment and chemotherapy are the curative approaches used to suppress prostate cancer progression. However, drug resistance is extensively and hard to overcome even though remarkable progress has been made in recent decades. Noncoding RNAs, such as miRNAs, lncRNAs, and circRNAs, are a group of cellular RNAs which participate in various cellular processes and diseases. Recently, accumulating evidence has highlighted the vital role of non-coding RNA in the development of drug resistance in prostate cancer. In this review, we summarize the important roles of these three classes of noncoding RNA in drug resistance and the potential therapeutic applications in this disease.